Opinions Plus

Perspectives on issues affecting biopharma and health care.

Radiologists supervise MRI

Opinions Plus

Why medtech is a different beast than biotech in the life sciences pack

By Jonathan P. Gertler

Bacteria

Opinions Plus

Microbiome drug development: a rapidly evolving field

By Peter Bak

Calculator close up

Opinions Plus

Early price setting, other market access planning is key for early-stage drug, device companies

By Christopher Leo, Christian Thienel, and Brendan Wang

IMMUNOTHERAPY lab

Opinions Plus

How to create successful leadership teams for cell and gene therapy companies

By Nick Stephens

Immunotherapies NIH lab

Opinions Plus

Biomarkers provide a bridge to the next frontier in immuno-oncology

By Grey Wilkinson

electronic med records

Opinions Plus

How to apply real-world evidence to outsmart cancer

By Christopher Boone and Viraj Narayanan

Help Wanted

Opinions Plus

To recruit top life sciences executives, companies need solid strategies in 2019

By Leslie Loveless

Kefauver-Harris Drug Amendments

Opinions Plus

A 1962 law slowed drug development. Changing it could slash drug prices

By Mary J. Ruwart

One bright pill

Opinions Plus

Inappropriate ‘interchangeability’ requirement for biosimilars will cost the U.S. billions

By Vijay Ramakrishnan and Edwin P. Ching

D.C. Insight IMAGE

Opinions Plus

Public distrust is high, PBMs are the problem, but the future is bright: a survey of biopharma pros

By Elizabeth Cooney

Medicine not covered

Opinions Plus

Rare diseases are losing their immunity in formulary exclusion lists

By Jeremy Schafer

D.C. Insight IMAGE

Opinions Plus

Tell us what you really think: A survey on drug prices, biotech, and Alex Azar

By Elizabeth Cooney

C-Suite illustration

Opinions Plus

From the C-suite: Biopharma execs teach students a lesson

By STAT staff

C-Suite illustration

Opinions Plus

From the C-Suite: nurturing diversity in the workplace

By STAT staff

Happy 2018

Opinions Plus

Industry insiders are upbeat about 2018, but that doesn’t mean more hiring

By Elizabeth Cooney

C-Suite illustration

Opinions Plus

From the C-Suite: advice on dealing with antsy investors

By STAT staff

C-Suite illustration

Opinions Plus

From the C-Suite: How to coach a team to respond to setbacks

By STAT staff

C-Suite illustration

Opinions Plus

From the C-Suite: How to learn leadership skills from mentors as diverse as Gen. Patton — and mom

By STAT staff

C-Suite illustration

Opinions Plus

From the C-Suite: How to build a strong workplace culture

By STAT staff

C-Suite illustration

Opinions Plus

From the C-Suite: Biopharma execs open up on what tests them as leaders

By STAT staff

C-Suite illustration

Opinions Plus

From the C-Suite: Biotech execs share their best interview questions — and the answers they want to hear

By STAT staff

Opioid Tablets

Opinions Plus

Doctors, beware: Prosecutors are zooming in on health care fraud as opioid crisis mounts

By Robert M. Thomas Jr.